about
Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosisOncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951TPA stimulation culture for improved detection of t(11;14)(q13;q32) in mantle cell lymphomaFast multiclonal clusterization of V(D)J recombinations from high-throughput sequencing.CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol.Diagnosis of intrachromosomal amplification of chromosome 21 (iAMP21) by molecular cytogenetics in pediatric acute lymphoblastic leukemiaNUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitorsCD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder.Value of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia.MYD88 L265P mutation in Waldenstrom macroglobulinemia.IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951.Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.Calibration of BCR-ABL1 mRNA quantification methods using genetic reference materials is a valid strategy to report results on the international scale.Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft.PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study.JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials.Follow-up of post-transplant minimal residual disease and chimerism in childhood lymphoblastic leukaemia: 90 d to react.Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol.Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes.Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia.Detection of a new heterozygous germline ETV6 mutation in a case with hyperdiploid acute lymphoblastic leukemia.High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones.Multi-loci diagnosis of acute lymphoblastic leukaemia with high-throughput sequencing and bioinformatics analysis.Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis.[Systemic EBV+ T-cell lymphoproliferative disease of childhood].Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR-JAK2 fusion transcript.Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy.Familial occurrence of thymoma and autoimmune diseases with the constitutional translocation t(14;20)(q24.1;p12.3).Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patientsIs apoptosis a massive process in myelodysplastic syndromes?Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapyFas/APO-1 (CD95) expression in myelodysplastic syndromesAcute myeloblastic leukemia (AML) with inv (16)(p13;q22) and the rare I type CBFbeta-MYH11 transcript: report of two new casesUnlike AML1, CBFbeta gene is not deregulated by point mutations in acute myeloid leukemia and in myelodysplastic syndromesExpression of HMGA2 in PB leukocytes and purified CD34+ cells from controls and patients with Myelofibrosis and myeloid metaplasiaSuccessful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantationParoxysmal nocturnal hemoglobinuria (PNH) and T cell large granular lymphocyte (LGL) leukemia--an unusual association: another cause of cytopenia in PNHGenetic polymorphisms in ARID5B, CEBPE, IKZF1 and CDKN2A in relation with risk of acute lymphoblastic leukaemia in adults: a Group for Research on Adult Acute Lymphoblastic Leukaemia (GRAALL) study
P50
Q24294760-CD159E45-428D-4392-B33C-5E698A50ECBCQ27852997-DE306967-0FD8-4185-9C50-F8E949775817Q28204365-2FA7B6C2-E7EB-420A-8E8D-82353513BC02Q28207718-7CCCB6A5-8C98-489D-AE06-493983A45D3EQ35178180-99E20071-0253-49F5-B4F8-C474E956854BQ36115668-7733B637-176F-4418-957E-618B11DE3D13Q36188346-636E6300-535E-4C41-89D4-E3F2A0C4D9BCQ37216300-12D68CD6-173A-40A7-A0EA-6A88DE2FECE0Q37216376-C0234F56-166B-4F6B-AFAA-A8D57C2D3969Q38633298-24586999-4525-408B-B5A6-655A4BC9A707Q39175169-FE1D3A85-D54B-4C80-A6C6-54D2F57210D1Q41688725-A7FF0C4F-AF7C-4389-AB73-85993F9EB359Q44071998-71AFF57B-40AD-4789-9F7E-495B47E6AD0FQ44671240-D97D96F7-E887-4CD2-A825-81777048F729Q44690658-B3DB070D-21E8-4AC1-9C92-1FF1BE97A385Q45934886-4ECFBA5B-3187-469C-BF8C-6DCCF11A6325Q46743360-A0CA5023-4394-447A-94DA-E5420A0DF39DQ47175107-EEB37A35-387D-4BA1-9A98-0A98685416B0Q47209362-782FB2F6-D788-4F49-9866-D94251DCDF05Q47222018-5434404D-C6A5-4CED-9AFE-BE189507E811Q47919057-A4E06C65-1EFE-49E2-A2C6-741E2D950B8DQ48159794-7FE6E93D-109D-4449-B90B-C60CDD0A2761Q48184463-A91F6AAC-1893-496E-848B-B7EAFBFBD781Q50111310-08835AFA-A4CA-4D41-B69D-9459938393A8Q50230268-C3AE3343-DEC0-4DBA-87FE-31E424C4FD34Q50887405-EBCED60F-08FE-47D7-B4BD-CFC608714E31Q54194391-F52012D5-DF82-45F5-A340-D988E40E7D3BQ54210991-B5532165-19EC-420D-8B43-1D74265FDE4DQ54550221-99148568-AA5B-48CB-981C-834E00B08F1EQ54660088-07D80397-D510-4659-8675-690E6F4C071BQ60585131-C1DA96E5-20A1-4204-998B-972DB4816754Q71751722-DB286209-2944-4F47-9A39-6EF5B3EC6F00Q74677616-8C5B12BF-235C-4FC5-A273-188DD3B2A68EQ77132466-11F01E48-27C1-485B-81FA-249BA9C1CE23Q77628527-FE00E3C0-2DB4-446B-8DFD-3CB64B6178FAQ78033530-DAA856D7-CF17-4428-A51F-757D330BF279Q79300663-34E49C96-446D-478E-A040-3F01BCA19DB9Q80442349-C3541CF0-A783-4D0C-AD56-600CF27CBCA0Q85552142-3E1B3A98-2628-43CE-9D3A-9C8A746CE782Q87386304-574A84EA-3CC7-4ADE-A979-896F6C582D46
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nathalie Grardel
@ast
Nathalie Grardel
@en
Nathalie Grardel
@es
Nathalie Grardel
@nl
Nathalie Grardel
@sl
type
label
Nathalie Grardel
@ast
Nathalie Grardel
@en
Nathalie Grardel
@es
Nathalie Grardel
@nl
Nathalie Grardel
@sl
prefLabel
Nathalie Grardel
@ast
Nathalie Grardel
@en
Nathalie Grardel
@es
Nathalie Grardel
@nl
Nathalie Grardel
@sl
P106
P21
P31
P496
0000-0001-6573-1312